Nothing Special   »   [go: up one dir, main page]

BR0318491A - Method for Reconstituting Damaged Cells by Cancer Treatment - Google Patents

Method for Reconstituting Damaged Cells by Cancer Treatment

Info

Publication number
BR0318491A
BR0318491A BRPI0318491-9A BR0318491A BR0318491A BR 0318491 A BR0318491 A BR 0318491A BR 0318491 A BR0318491 A BR 0318491A BR 0318491 A BR0318491 A BR 0318491A
Authority
BR
Brazil
Prior art keywords
cells
cancer treatment
cell
primate mammal
reconstituting
Prior art date
Application number
BRPI0318491-9A
Other languages
Portuguese (pt)
Inventor
Donnie Rudd
Original Assignee
Regenetech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenetech Inc filed Critical Regenetech Inc
Publication of BR0318491A publication Critical patent/BR0318491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODO PARA RECONSTITUIR AS CéLULAS DANIFICADAS PELO TRATAMENTO DO CáNCER". é aqui divulgado um método para reconstituir células danificadas pelo tratamento do câncer. O método compreende remover as células sangüíneas de um mamífero primata, expandir controlavelmente as células a uma razão que produza um fator de expansão de pelo menos 700% dentro de 7 dias enquanto se mantém a sua geometria tridimensional, seu suporte de célula para célula e sua geometria de célula para célula, remover quaisquer materiais tóxicos das células sangüíneas, e re-introduzir as células dentro do mamífero primata dentro de um período de tempo suficiente para prevenir o mamífero primata de sofrer decréscimo de mobilidade devido a perda de células hematopoiéticas ou outras."METHOD FOR RECONSTITUTING CELLS DAMAGED BY CANCER TREATMENT". Disclosed herein is a method for reconstructing cells damaged by cancer treatment. The method comprises removing blood cells from a primate mammal, controllably expanding cells at a rate producing at least 700% expansion factor within 7 days while maintaining their three-dimensional geometry, cell-to-cell support and cell-to-cell geometry, remove any toxic materials from blood cells, and re-introduce the cells into the primate mammal within a sufficient time to prevent the primate mammal from decreasing mobility due to loss of hematopoietic or other cells.

BRPI0318491-9A 2003-09-02 2003-09-02 Method for Reconstituting Damaged Cells by Cancer Treatment BR0318491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/027248 WO2005032566A1 (en) 2003-09-02 2003-09-02 Method of replenishing cells damaged by treatment for cancer

Publications (1)

Publication Number Publication Date
BR0318491A true BR0318491A (en) 2006-09-12

Family

ID=34421164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318491-9A BR0318491A (en) 2003-09-02 2003-09-02 Method for Reconstituting Damaged Cells by Cancer Treatment

Country Status (6)

Country Link
EP (1) EP1660105A1 (en)
JP (1) JP2007521236A (en)
CN (1) CN1826125A (en)
BR (1) BR0318491A (en)
CA (1) CA2537314A1 (en)
WO (1) WO2005032566A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634949B (en) * 2013-04-23 2018-09-11 獨立行政法人產業技術綜合研究所 Method for producing catalyst for cyclic

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635387A (en) * 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5277701A (en) * 1991-11-15 1994-01-11 Regents Of The University Of Minnesota Treatment of aluimmunization and refractoriness to platelet transfusion by protein A column therapy
US6436387B1 (en) * 1992-11-24 2002-08-20 G.D. Searle & Co. Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins
DE4240635C2 (en) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Multiplication of hematopoietic progenitor cells ex vivo and compositions of hematopoietic growth factors
US5702941A (en) * 1993-09-09 1997-12-30 Synthecon, Inc. Gas permeable bioreactor and method of use
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells

Also Published As

Publication number Publication date
JP2007521236A (en) 2007-08-02
CN1826125A (en) 2006-08-30
WO2005032566A1 (en) 2005-04-14
CA2537314A1 (en) 2005-04-14
EP1660105A1 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
Palmoski et al. Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritic cartilage
DE60238416D1 (en) PLASMA PROTEIN MATRITZES AND METHOD FOR THEIR PRODUCTION
BRPI0418326A (en) tissue regeneration method
BRPI0407221A (en) Wharton Jelly Extract, Method for Obtaining a Human Parent Cell, Methods for Producing a Cell Population, Cell Populations, and Method for Producing Bone Tissue
BRPI0509678A (en) particles of a viscoelastic medium, method for producing injectable gel particles of a viscoelastic medium, implant for soft tissue augmentation, method for enlarging mammalian soft tissue, injectable gel particles, and use of injectable gel particles for a medium. viscoelastic
BR9713412A (en) Cosmetic composition suitable for topical application to the skin or hair and cosmetic treatment process
BR0214065A (en) Method and apparatus for producing a skin graft and graft produced in this manner
ES2054676T3 (en) REGULATION OF SPECIFIC SEED TRANSCRIPTION.
MA23744A1 (en) PROCESS FOR THE PREPARATION OF SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE
BR0207811A (en) Substituted aryl and heteroaryl urea compounds useful in treating diseases
EA200001223A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
WO2003001982A3 (en) Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
BRPI0408256A (en) compound, methods of treating a human or animal by limiting cell replication, suffering from cancer, suffering from a neoplastic disease, and suffering from proliferative diseases, use of a compound, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof
BR0210599A (en) Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium
CN103282033A (en) Compounds and methods for skin repair
RU94044456A (en) Agent for suppression of dysfunctional uterine bleeding
BR0016847A (en) Fluid compositions containing ester
BR0318491A (en) Method for Reconstituting Damaged Cells by Cancer Treatment
WO2005017160A3 (en) Mobilization of hematopoietic cells
BR9814913A (en) New substance kf-1040 and process for producing it
BR9711104B1 (en) A process for preparing a polydispersed saccharide composition, polydispersed saccharide composition and product comprising a polydispersed saccharide composition.
BR0312179A (en) Process for the preparation of epik5-n-o-supersulfate derivative, pharmaceutical composition and cosmetic composition containing it and its use
ATE215550T1 (en) REGIOSELECTIVE SULPHATION
ES2036174T3 (en) A PROCEDURE FOR THE PREPARATION OF A BRONCHODILATOR COMBINATION OF PRAZOSIN-PIRBUTEROL.
DE69132050D1 (en) COMPOSITIONS OF GROWTH FACTORS, PRODUCTION AND USE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.